(4R)-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-tert-butyl ester | 1266739-94-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-tert-butyl ester
• 英文别名: 1-Benzyl 5-tert-butyl 2-oxoimidazolidine-1,5-dicarboxylate；1-O-benzyl 5-O-tert-butyl 2-oxoimidazolidine-1,5-dicarboxylate
• CAS: 1266739-94-9
• 化学式: C₁₆H₂₀N₂O₅
• 分子量: 320.345
• InChiKey: BQZKFYBNKNXMIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4R)-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-tert-butyl ester 生成 5-(1,1-dimethylethyl) 1-(phenylmethyl) 3-methyl-2-oxo-1,5-imidazolidinedicarboxylate
  参考文献：
  名称：

  YONEDA, NAOTO;KATO, JYOJI;KINASHI, KEIZO

  摘要：

  DOI：
• 作为产物：
  描述：

  (S)-(-)-2-氧代-1,5-咪唑烷二羧酸 1-苄酯 生成 (4R)-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-tert-butyl ester
  参考文献：
  名称：

  YONEDA, NAOTO;KATO, JYOJI;KINASHI, KEIZO

  摘要：

  DOI：

文献信息

• 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
  申请人：——

  公开号：US20010041710A1

  公开（公告）日：2001-11-15

  The present invention relates to a compound of the formula 1 wherein R 1 , R 2 , R 3 and R 4 are as defined above, and pharmaceutically acceptable salts and solvates thereof, that are useful, for example, as matrix metalloproteinase inhibitors. The present invention is also directed to pharmaceutical compositions comprising such compounds and methods of treatment for diseases such as osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, tissue ulceration, restinosis, periodontal disease, inflammation, epidermolysis bullosa, scleritis, stroke, Alzheimer's disease, and the like, characterized by inappropriate matrix metalloproteinase activity. Processes for the synthesis of compounds of formula (I) are also disclosed.

  本发明涉及一种公式1的化合物，其中R1，R2，R3和R4如上所定义，并且其药学上可接受的盐和溶剂，例如作为基质金属蛋白酶抑制剂。本发明还涉及包含这种化合物的制药组合物和治疗疾病的方法，例如骨关节炎，类风湿性关节炎，癌症，骨质疏松，组织溃疡，再狭窄，牙周疾病，炎症，表皮松解性疾病，巩膜炎，中风，阿尔茨海默病等，其特征是基质金属蛋白酶活性不适当。本发明还公开了化合物公式（I）的合成方法。
• CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT
  申请人：Cumming Jared N.

  公开号：US20090312341A1

  公开（公告）日：2009-12-17

  Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is X is —O—, —C(R 14 ) 2 — or —N(R)—; Z is —C(R 14 ) 2 — or —N(R)—; t is 0, 1, 2 or 3; each R and R 2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R 14 is H, alkyl, alkenyl, alkynyl, halo, —CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, —OR 35 , —N(R 24 ) (R 25 ) or —SR 35 ; R 41 is alkyl, cycloalkyl, —SO 2 (alkyl), —C(O)-alkyl, —C(O)-cycloalkyl or -alkyl-NH—C(O)CH 3 ; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I. Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

  本发明涉及公式I的新化合物或其药学上可接受的盐或溶剂，其中R1为X为—O—，—C（R14）2—或—N（R）—；Z为—C（R14）2—或—N（R）—；t为0、1、2或3；每个R和R2独立地为H，烷基，环烷基，环烷基烷基，芳基，杂芳基，杂环烷基，芳基烷基，杂芳基烷基，杂环烷基烷基，烯基或炔基；每个R14为H，烷基，烯基，炔基，卤素，—CN，卤代烷基，环烷基，环烷基烷基，芳基，杂芳基，杂环烷基，芳基烷基，杂芳基烷基，杂环烷基烷基，—OR35，—N（R24）（R25）或—SR35；R41为烷基，环烷基，—SO2（烷基），—C（O）-烷基，—C（O）-环烷基或-烷基-NH-C（O）CH3；其余变量如规范中所定义。本发明还涉及包含公式I化合物的制药组合物以及使用公式I化合物治疗认知或神经退行性疾病的方法。本发明还涉及包含公式I化合物的制药组合物和治疗方法，其中该组合物与其他对治疗认知或神经退行性疾病有用的药物一起使用。
• 咪唑啉酮衍生物及其用途
  申请人：南京医工医药技术有限公司

  公开号：CN114736197B

  公开（公告）日：2022-09-13

  本发明提供一类咪唑啉酮衍生物及其用途，所述咪唑啉酮衍生物是具有下列式(I)或(II)所示结构的化合物或其药学上可接受的盐、立体异构体。本发明化合物具有显著的RIP1激酶抑制活性，可用于治疗与RIP1激酶相关的疾病，特别是各类炎症疾病。或
• 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases
  申请人：Pfizer Products Inc.

  公开号：EP1134215A1

  公开（公告）日：2001-09-19

  The present invention relates to a compound of the formula wherein R1, R2, R3 and R4 are as defined above, and pharmaceutically acceptable salts and solvates thereof, that are useful, for example, as matrix metalloproteinase inhibitors. The present invention is also directed to pharmaceutical compositions comprising such compounds and methods of treatment for diseases such as osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, tissue ulceration, restinosis, periodontal disease, inflammation, epidermolysis bullosa, scleritis, stroke, Alzheimer's disease, and the like, characterized by inappropriate matrix metalloproteinase activity. Processes for the synthesis of compounds of formula (I) are also disclosed.

  本发明涉及如下式的化合物 其中R1、R2、R3和R4如上定义，及其药学上可接受的盐和溶液，可用作基质金属蛋白酶抑制剂等。本发明还涉及包含此类化合物的药物组合物以及治疗疾病的方法，这些疾病包括骨关节炎、类风湿性关节炎、癌症、骨质疏松症、组织溃疡、再狭窄、牙周病、炎症、表皮松解症、硬膜炎、中风、老年痴呆症等，其特征在于基质金属蛋白酶活性不适当。还公开了式（I）化合物的合成工艺。
• MAEDA, HIROSHI;SUZUKI, MAMORU;SUGANO, HIROSHI;YAMAMURA, MICHIO;ISHIDA, RY+, INT. J. PEPTIDE AND PROTEIN RES., 33,(1989) N, C. 403-411
  作者：MAEDA, HIROSHI、SUZUKI, MAMORU、SUGANO, HIROSHI、YAMAMURA, MICHIO、ISHIDA, RY+

  DOI：——

  日期：——